Combined pre- and postsynatic action of IgG antibodies in Miller Fisher syndrome

Neurology

Volumn 56, Issue 1, 2001, Pages 67-74

  Buchwald, B ^a,e   Bufler, J ^a,b   Carpo, M ^a,c   Heidenreich, F ^a,d   Pitz, R ^a,b   Dudel, J ^a,b   Nobile Orazio, E ^a,c   Toyka, K V ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c UNIVERSITY OF MILAN   (Italy)

^d HANNOVER MEDICAL SCHOOL   (Germany)

^e UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; GUILLAIN BARRE SYNDROME; HUMAN; PRIORITY JOURNAL; ADULT; AGED; ANIMAL; BAGG ALBINO MOUSE; CELL CULTURE; CYTOLOGY; DRUG EFFECT; EXCITATORY POSTSYNAPTIC POTENTIAL; FEMALE; IMMUNOLOGY; ISOLATION AND PURIFICATION; MALE; METABOLISM; MIDDLE AGED; MOUSE; MUSCLE CELL; PATCH CLAMP; PHYSIOLOGY; SYNAPSE; SYNAPTIC TRANSMISSION;

ACETYLCHOLINE; AGENTS INTERACTING WITH TRANSMITTER, HORMONE OR DRUG RECEPTORS; AUTOANTIBODY; GANGLIOSIDE; GQ1B GANGLIOSIDE; IMMUNOGLOBULIN G; NICOTINIC RECEPTOR; VASODILATOR AGENT;

ACETYLCHOLINE; ADULT; AGED; ANIMALS; AUTOANTIBODIES; CELLS, CULTURED; EXCITATORY POSTSYNAPTIC POTENTIALS; FEMALE; GANGLIOSIDES; HUMANS; IMMUNOGLOBULIN G; MALE; MICE; MICE, INBRED BALB C; MIDDLE AGED; MILLER FISHER SYNDROME; MUSCLE FIBERS; NEUROTRANSMITTER AGENTS; PATCH-CLAMP TECHNIQUES; RECEPTORS, NICOTINIC; SYNAPSES; SYNAPTIC TRANSMISSION; VASODILATOR AGENTS;

EID: 0035830321     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/wnl.56.1.67     Document Type: Article

References (46)

1. An unusual variant of acute idiopathic polyneuritis (syndrome of ophthalmoplegia, ataxia and areflexia)
2. Serum IgG antibody to ganglioside GQ1b is a possible marker of Miller Fisher syndrome
3. Frequent presence of anti-GQ1b antibody in Fisher's syndrome
4. Clinical correlate and fine specificity of anti-GQ1b antibodies in peripheral neuropathy
5. Localization of GM1 and Ga1(β1-3) GalNAc antigenic determinants in peripheral nerve
6. Serum factor in Miller-Fisher variant of Guillain-Barré syndrome and neurotransmitter release
7. Immunoglobulin G from patient with Miller-Fisher syndrome rapidly and reversibly depresses evoked quantal release at the neuromuscular junction of mice
8. Pre- and postsynaptic blockade of neuromuscular transmission by Miller-Fisher syndrome IgG at mouse motor nerve terminals
9. Miller Fisher anti-GQ1b antibodies: α-latrotoxin-like effects on motor end plates
10. Miller Fisher syndrome
11. Randomised trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain-Barré syndrome
12. The not-so-benign Miller Fisher syndrome: A variant of the Guillain-Barré syndrome
13. A new method for purification of anti-glycosphingolipid antibody. Avian Hematoside (NeucGc) antibody
14. Myasthenia gravis: Long-term correlation of binding and bungarotoxin blocking against acetylcholine receptors with changes in disease severity
15. The spectrum of immune responses to Campylobacter jejuni and glycoconjugates in Guillain-Barré syndrome and in other neuroimmunological disorders
16. Electrophysiological classification of Guillain-Barré syndrome: Clinical associations and outcome
17. Calcium dependence of quantal release triggered by graded depolarization pulses to nerve terminals on crayfish and frog muscle
18. Neuromuscular blockade by IgG antibodies from patients with Guillain-Barré syndrome: A macro-patch-clamp study
19. Activation and desensitization of embryonic-like receptor channels in mouse muscle by acetylcholine concentration steps
20. Improved patch-clamp techniques for high-resolution current recording from cells and cell-free patches
21. Purified IgG from seropositive and seronegative patients with myasthenia gravis reversibly blocks currents through nicotinic acetylcholine receptor channels
22. Liquid filament switch for ultrafast exchanges of solutions at excised patches of synaptic membrane of crayfish muscle
23. Open channel block by physiostigmine and procaine in embryonic-like nicotinic receptors of mouse muscle
24. Open channel and competitive block of the embryonic form of the nicotinic receptor of mouse myotubes by (+)-tubocurarine
25. Antibodies to motor nerve terminals: An electrophysiological study of a human myasthenic syndrome transferred to mouse
26. The effect of myasthenic syndrome antibody on presynaptic calcium channels in the mouse
27. Quantal acetylcholine release at the vertebrate neuromuscular junction
28. Monoclonal antibodies raised against Guillain-Barré syndrome-associated Campylobacter jejuni lipopolysaccharides react with neuronal gangliosides and paralyze muscle-nerve preparations
29. Myasthenia gravis: Study of humoral immune mechanisms by passive transfer to mice
30. Activation and blockade of mouse muscle nicotinic channels by antibodies directed against the binding site of the acetylcholine receptor
31. Seronegative myasthenia gravis. Evidence for plasma factor(s) interfering with acetylcholine receptor function
32. Anti-ganglioside antibody and neuropathy: Review of our research
33. Serum anti-GQ1b IgG antibody is associated with ophthalmoplegia in Miller Fisher syndrome and Guillain-Barré syndrome: Clinical and immunohistochemical studies
34. Ganglioside composition of the human cranial nerves, with special reference to pathophysiology of Miller Fisher syndrome
35. Measurement and significance of antibodies against GM1 ganglioside
36. A comparative trial of anti-glycoconjugate antibody assays: IgM antibodies to GM1
37. Binding affinities between human peripheral nerve GM1 and anti-GM1 antibodies
38. Gangliosides and glycosphingolipids of peripheral nervous system myelins: A minireview
39. Why are eye muscles frequently involved in myasthenia gravis?
40. Fisher syndrome with tetraparesis and antibody to GQ1b: Evidence for motor nerve terminal block
41. Anti-acetylcholine receptor antibodies directed against the α-bungarotoxin binding site induce a unique form of experimental myasthenia
42. Effects of monoclonal anti-acetylcholine receptor antibody on the avian endplate
43. Adaption of quantal content to decreased postsynaptic sensitivity at single end-plates in alpha bungarotoxin-treated rats
44. Acetylcholine release in myasthenia gravis: Regulation at single end-plate level